Company press releases

Viser 1 - 50 av 68 resultater
Tid Selskap Tittel Sektor Kategori
04 Dec 2025
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates 20103010 Biotechnology Meetings / events
25 Nov 2025
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 20103010 Biotechnology Other subject
06 Nov 2025
17:31 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 20103010 Biotechnology Meetings / events
03 Nov 2025
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Present at Upcoming Conferences 20103010 Biotechnology Meetings / events
06 Oct 2025
20:48 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million 20103010 Biotechnology Change in Capital
04 Sep 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates 20103010 Biotechnology Corporate life
27 Aug 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 20103010 Biotechnology Other subject
27 Jun 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences 20103010 Biotechnology Meetings / events
24 Jun 2025
15:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting 20103010 Biotechnology General meeting / Board Meeting
17 Jun 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress 20103010 Biotechnology Corporate life
11 Jun 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 20103010 Biotechnology Meetings / events
06 Jun 2025
09:45 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 20103010 Biotechnology Meetings / events
27 May 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat 20103010 Biotechnology Corporate life
13 May 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025 20103010 Biotechnology General meeting / Board Meeting
29 Apr 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
24 Apr 2025
18:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million 20103010 Biotechnology Other financial transaction
17 Apr 2025
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025 20103010 Biotechnology Other subject
19 Feb 2025
18:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers 20103010 Biotechnology Meetings / events
11 Feb 2025
18:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 20103010 Biotechnology Meetings / events
14 Jan 2025
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease 20103010 Biotechnology Other subject
10 Dec 2024
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease 20103010 Biotechnology Corporate life
09 Dec 2024
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function 20103010 Biotechnology Other subject
04 Dec 2024
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 20103010 Biotechnology Other subject
26 Oct 2024
09:30 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 20103010 Biotechnology Meetings / events
11 Oct 2024
15:20 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 20103010 Biotechnology Meetings / events
01 Oct 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event 20103010 Biotechnology Meetings / events
12 Sep 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease 20103010 Biotechnology Corporate life
05 Sep 2024
18:12 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association 20103010 Biotechnology Change in Capital
05 Sep 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 20103010 Biotechnology Meetings / events
18 Jul 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease 20103010 Biotechnology Other subject
09 Jul 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease 20103010 Biotechnology Other subject
21 Jun 2024
15:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting 20103010 Biotechnology General meeting / Board Meeting
23 May 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease 20103010 Biotechnology Corporate life
15 May 2024
07:00 CEST 		VIVORYON Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 20103010 Biotechnology Corporate life
08 May 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 20103010 Biotechnology General meeting / Board Meeting
24 Apr 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates 20103010 Biotechnology Corporate life
16 Apr 2024
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 20103010 Biotechnology Other subject
15 Mar 2024
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces Changes to Board Composition 20103010 Biotechnology Corporate life
04 Mar 2024
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease 20103010 Biotechnology Corporate life
08 Jan 2024
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 20103010 Biotechnology Meetings / events
06 Dec 2023
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress 20103010 Biotechnology Corporate life
28 Nov 2023
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 20103010 Biotechnology Other subject
07 Nov 2023
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference 20103010 Biotechnology Meetings / events
26 Oct 2023
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision 20103010 Biotechnology Other subject
23 Oct 2023
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose 20103010 Biotechnology Other subject
17 Oct 2023
15:32 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders 20103010 Biotechnology Meetings / events
05 Oct 2023
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation 20103010 Biotechnology Other subject
15 Sep 2023
13:57 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board 20103010 Biotechnology General meeting / Board Meeting
07 Sep 2023
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress 20103010 Biotechnology Other subject
31 Aug 2023
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023 20103010 Biotechnology Other subject